Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moolec Science's revenue per share for the
six
months ended in Dec. 2025 was $7.20.
Moolec Science's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $781.24.
Warning Sign:
Moolec Science SA revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Moolec Science was -34.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Moolec Science's Revenue per Share or its related term are showing as below:
MLEC's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.1 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Moolec Science Revenue per Share Related Terms
Moolec Science Revenue per Share Historical Data
* Premium members only.
The historical data trend for Moolec Science's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs CELZ, DRMA, ENVB: Revenue per Share Comparison
For the Biotechnology subindustry, Moolec Science's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's PS Ratio distribution charts can be found below:
* The bar in red indicates where Moolec Science's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Moolec Science's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $781.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a Revenue per Share of $781.24 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #999999 out of 767 companies in the Biotechnology industry.
Is Moolec Science's Revenue per Share too high?
Moolec Science's current Revenue per Share is $781.24. The Biotechnology industry median Revenue per Share is 3.10. Moolec Science's value of $781.24 is 25101.3% above this industry median. Based on the distribution chart, Moolec Science ranks #999999 out of 767 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moolec Science has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's Revenue per Share compare to CELZ and DRMA?
According to the Biotechnology industry distribution chart, Moolec Science ranks #999999 out of 767 companies for Revenue per Share. This places Moolec Science in the lower half of its industry. The industry median Revenue per Share is 3.10. Moolec Science's value of $781.24 is 25101.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moolec Science's current Revenue per Share of $781.24 is 25101.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Moolec Science and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moolec Science's current Revenue per Share is $781.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $6.80 — trading 92% below its estimated fair value. The current Revenue per Share is $781.24 and 25101.3% above the Biotechnology industry median of 3.10. Moolec Science's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Moolec Science (MLEC), the current Revenue per Share is $781.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $6.80 is trading 92% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
Revenue per Share: $781.24
GF Value™: $84.84 vs. price of $6.80 (92% below fair value)
Industry Position: 25101.3% above the Biotechnology median (#999999 of 767)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
42GF Score
Get the complete analysis for MLEC
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
